Pathogenesis of Renal Calculi

Urologic Clinics of North America

Volumn 34, Issue 3, 2007, Pages 295-313

  Miller, Nicole L ^a,b   Evan, Andrew P ^a,b   Lingeman, James E ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Indiana Kidney Stone Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCIUM OXALATE; CALGRANULIN; CITRIC ACID; GLYCOSAMINOGLYCAN; MAGNESIUM; OSTEOPONTIN; PROTEIN; PROTHROMBIN; PYROPHOSPHATE; TAMM HORSFALL GLYCOPROTEIN; ULINASTATIN;

BACTERIUM; CRYSTALLIZATION; GLYCOSYLATION; HISTOPATHOLOGY; HUMAN; KIDNEY INJURY; KIDNEY TUBULE; NEPHROLITHIASIS; PATHOGENESIS; PERCUTANEOUS NEPHROLITHOTOMY; PHOSPHORYLATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; STONE FORMATION; UNITED STATES;

CALCIUM OXALATE; CALCIUM PHOSPHATES; HUMANS; KIDNEY CALCULI; RISK FACTORS;

EID: 34547520949     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2007.05.007     Document Type: Review

References (119)

1. Stamatelou K.K., Francis M.E., Jones C.A., et al. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 63 5 (2003) 1817-1823
2. Evan A.P., Coe F.L., Lingeman J.E., et al. Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int 69 12 (2006) 2227-2235
3. Evan A.P., Coe F.L., Rittling S.R., et al. Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization. Kidney Int 68 1 (2005) 145-154
4. Evan A.P., Lingeman J.E., Coe F.L., et al. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 111 5 (2003) 607-616
5. Evan A.P., Lingeman J.E., Coe F.L., et al. Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int 67 2 (2005) 576-591
6. Coe F.L., Evan A., and Worcester E. Kidney stone disease. J Clin Invest 115 10 (2005) 2598-2608
7. Brown C.M., Ackermann D.K., and Purich D.L. EQUIL93: a tool for experimental and clinical urolithiasis. Urol Res 22 2 (1994) 119-126
8. Werness P.G., Brown C.M., Smith L.H., et al. EQUIL2: a BASIC computer program for the calculation of urinary saturation. J Urol 134 6 (1985) 1242-1244
9. Parks J.H., Coward M., and Coe F.L. Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int 51 3 (1997) 894-900
10. Asplin J.R., Parks J.H., Nakagawa Y., et al. Reduced crystallization inhibition by urine from women with nephrolithiasis. Kidney Int 61 5 (2002) 1821-1829
11. Asplin J.R., Parks J.H., and Coe F.L. Dependence of upper limit of metastability on supersaturation in nephrolithiasis. Kidney Int 52 6 (1997) 1602-1608
12. Brown C., and Purich D. Physical chemical processes in kidney stone formation. In: Coe F.L., and Favus M.J. (Eds). Disorders of bone and mineral metabolism (1992), Raven Press, New York 613-624
13. Khan S.R. Calcium phosphate/calcium oxalate crystal association in urinary stones: implications for heterogeneous nucleation of calcium oxalate. J Urol 157 1 (1997) 376-383
14. Garside J. Nucleation. In: Nancollas G.H. (Ed). Biological mineralization and demineralization (1982), Springer-Verlag, New York 23-25
15. Jenkins A.D. Calculous formation. In: Gillenwater J.Y., Grayhack J.T., Howards S.S., et al. (Eds). Adult and pediatric urology. 4th edition vol. 1 (2002), Lippincott Williams and Wilkins, Philadelphia 356-392
16. Srinivasan S., Kalaiselvi P., and Varalakshmi P. Epitaxial deposition of calcium oxalate on uric acid rich stone matrix is induced by a 29 kDa protein. Clin Chim Acta 364 1-2 (2006) 267-274
17. Koutsoukos P.G., Lam-Erwin C.Y., and Nancollas G.H. Epitaxial considerations in urinary stone formation. I. The urate-oxalate-phosphate system. Invest Urol 18 2 (1980) 178-184
18. Pak C.Y., and Arnold L.H. Heterogeneous nucleation of calcium oxalate by seeds of monosodium urate. Proc Soc Exp Biol Med 149 4 (1975) 930-932
19. Coe F.L., Lawton R.L., Goldstein R.B., et al. Sodium urate accelerates precipitation of calcium oxalate in vitro. Proc Soc Exp Biol Med 149 4 (1975) 926-929
20. Burns J.R., and Finlayson B. The effect of seed crystals on calcium oxalate nucleation. Invest Urol 18 2 (1980) 133-136
21. Meyer J.L., Bergert J.H., and Smith L.H. The epitaxially induced crystal growth of calcium oxalate by crystalline uric acid. Invest Urol 14 2 (1976) 115-119
22. Nielsen A.E., and Christoffersen J. The mechanisms of crystal growth and dissolution. In: Nancollas G.H. (Ed). Biological mineralization and demineralization (1982), Springer-Verlag, New York 37-77
23. Kok D.J., Papapoulos S.E., and Bijvoet O.L. Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int 37 1 (1990) 51-56
24. Kok D.J., and Khan S.R. Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 46 3 (1994) 847-854
25. Vermeulen C.W., and Lyon E.S. Mechanisms of genesis and growth of calculi. Am J Med 45 5 (1968) 684-692
26. Finlayson B., and Reid F. The expectation of free and fixed particles in urinary stone disease. Invest Urol 15 6 (1978) 442-448
27. Evan A., Lingeman J., Coe F.L., et al. Randall's plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int 69 8 (2006) 1313-1318
28. Low R.K., and Stoller M.L. Endoscopic mapping of renal papillae for Randall's plaques in patients with urinary stone disease. J Urol 158 6 (1997) 2062-2064
29. Khan S.R. Calcium oxalate crystal interaction with renal tubular epithelium, mechanism of crystal adhesion and its impact on stone development. Urol Res 23 2 (1995) 71-79
30. Bigelow M.W., Wiessner J.H., Kleinman J.G., et al. Surface exposure of phosphatidylserine increases calcium oxalate crystal attachment to IMCD cells. Am J Physiol 272 1 Pt 2 (1997) F55-F62
31. Mandel N. Mechanism of stone formation. Semin Nephrol 16 5 (1996) 364-374
32. Lieske J.C., Toback F.G., and Deganello S. Sialic acid-containing glycoproteins on renal cells determine nucleation of calcium oxalate dihydrate crystals. Kidney Int 60 5 (2001) 1784-1791
33. Verkoelen C.F., van der Boom B.G., Kok D.J., et al. Sialic acid and crystal binding. Kidney Int 57 3 (2000) 1072-1082
34. Yamate T., Kohri K., Umekawa T., et al. Interaction between osteopontin on madin darby canine kidney cell membrane and calcium oxalate crystal. Urol Int 62 2 (1999) 81-86
35. Verkoelen C.F. Crystal retention in renal stone disease: a crucial role for the glycosaminoglycan hyaluronan?. J Am Soc Nephrol 17 6 (2006) 1673-1687
36. Verkoelen C.F., Van Der Boom B.G., and Romijn J.C. Identification of hyaluronan as a crystal-binding molecule at the surface of migrating and proliferating MDCK cells. Kidney Int 58 3 (2000) 1045-1054
37. Worcester E.M. Inhibitors of stone formation. Semin Nephrol 16 5 (1996) 474-486
38. Malek R.S., and Boyce W.H. Observations on the ultrastructure and genesis of urinary calculi. J Urol 117 3 (1977) 336-341
39. Hess B., Nakagawa Y., and Coe F.L. Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol 257 1 Pt 2 (1989) F99-F106
40. Hess B., Nakagawa Y., Parks J.H., et al. Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol 260 4 Pt 2 (1991) F569-F578
41. Hess B., Jordi S., Zipperle L., et al. Citrate determines calcium oxalate crystallization kinetics and crystal morphology-studies in the presence of Tamm-Horsfall protein of a healthy subject and a severely recurrent calcium stone former. Nephrol Dial Transplant 15 3 (2000) 366-374
42. Hess B., Zipperle L., and Jaeger P. Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 265 6 Pt 2 (1993) F784-F791
43. Malek R.S., and Boyce W.H. Intranephronic calculosis: its significance and relationship to matrix in nephrolithiasis. J Urol 109 4 (1973) 551-555
44. Boyce W.H. Organic matrix of human urinary concretions. Am J Med 45 5 (1968) 673-683
45. Williams Jr. J.C., Zarse C.A., Jackson M.E., et al. Variability of protein content in calcium oxalate monohydrate stones. J Endourol 20 8 (2006) 560-564
46. Boyce W.H. Proteinuria in kidney calculous disease. In: Manuel Y., Revillard J., and Betuel H. (Eds). Proteins in normal and pathological urine (1970), University Park Press, Baltimore 235-243
47. Allen T.D., and Spence H.M. Matrix stones. J Urol 95 3 (1966) 284-290
48. Stacholy J., and Goldberg E.P. Microstructural matrix-crystal interactions in calcium oxalate monohydrate kidney stones. Scan Electron Microsc Pt 2 (1985) 781-787
49. Khan S.R., and Hackett R.L. Role of organic matrix in urinary stone formation: an ultrastructural study of crystal matrix interface of calcium oxalate monohydrate stones. J Urol 150 1 (1993) 239-245
50. Finlayson B. Symposium on renal lithiasis. Renal lithiasis in review. Urol Clin North Am 1 2 (1974) 181-212
51. Boyce W.H., and King J.S. Immunological studies of renal calculi and urinary macromolecules. Rein Foie 4 (1962) II/13-II/21
52. Moore S., and Gowland G. The immunological integrity of matrix substance A and its possible detection and quantitation in urine. Br J Urol 47 5 (1975) 489-494
53. Jones W.T., Waterhouse R.L., and Resnick M.I. The evaluation of urinary protein patterns in a stone-forming animal model using two-dimensional polyacrylamide gel electrophoresis. J Urol 145 4 (1991) 868-874
54. Kumar V., and Lieske J.C. Protein regulation of intrarenal crystallization. Curr Opin Nephrol Hypertens 15 4 (2006) 374-380
55. Khan S.R. Animal models of kidney stone formation: an analysis. World J Urol 15 4 (1997) 236-243
56. Khan S.R., Shevock P.N., and Hackett R.L. Urinary enzymes and calcium oxalate urolithiasis. J Urol 142 3 (1989) 846-849
57. Khan S.R. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 8 2 (2004) 75-88
58. Khan S.R. Renal tubular damage/dysfunction: key to the formation of kidney stones. Urol Res 34 2 (2006) 86-91
59. Asselman M., Verhulst A., De Broe M.E., et al. CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. J Am Soc Nephrol 14 12 (2003) 3155-3166
60. Asselman M., Verhulst A., Van Ballegooijen E.S., et al. Hyaluronan is apically secreted and expressed by proliferating or regenerating renal tubular cells. Kidney Int 68 1 (2005) 71-83
61. Khan S.R., Johnson J.M., Peck A.B., et al. Expression of osteopontin in rat kidneys: induction during ethylene glycol induced calcium oxalate nephrolithiasis. J Urol 168 3 (2002) 1173-1181
62. Riese R.J., Mandel N.S., Wiessner J.H., et al. Cell polarity and calcium oxalate crystal adherence to cultured collecting duct cells. Am J Physiol 262 2 Pt 2 (1992) F177-F184
63. Verkoelen C.F., van der Boom B.G., Houtsmuller A.B., et al. Increased calcium oxalate monohydrate crystal binding to injured renal tubular epithelial cells in culture. Am J Physiol 274 5 Pt 2 (1998) F958-F965
64. de Water R., Leenen P.J., Noordermeer C., et al. Cytokine production induced by binding and processing of calcium oxalate crystals in cultured macrophages. Am J Kidney Dis 38 2 (2001) 331-338
65. van Oostrom O., Velema E., Schoneveld A.H., et al. Age-related changes in plaque composition: a study in patients suffering from carotid artery stenosis. Cardiovasc Pathol 14 3 (2005) 126-134
66. de Water R., Boeve E.R., van Miert P.P., et al. Experimental nephrolithiasis in rats: the effect of ethylene glycol and vitamin D3 on the induction of renal calcium oxalate crystals. Scanning Microsc 10 2 (1996) 591-601 [discussion: 601-3]
67. Marengo S.R., Chen D.H., Kaung H.L., et al. Decreased renal expression of the putative calcium oxalate inhibitor Tamm-Horsfall protein in the ethylene glycol rat model of calcium oxalate urolithiasis. J Urol 167 5 (2002) 2192-2197
68. Robinson M., Pond C.L., Laurie R.D., et al. Subacute and subchronic toxicity of ethylene glycol administered in drinking water to Sprague-Dawley rats. Drug Chem Toxicol 13 1 (1990) 43-70
69. Eder A.F., McGrath C.M., Dowdy Y.G., et al. Ethylene glycol poisoning: toxicokinetic and analytical factors affecting laboratory diagnosis. Clin Chem 44 1 (1998) 168-177
70. Poldelski V., Johnson A., Wright S., et al. Ethylene glycol-mediated tubular injury: identification of critical metabolites and injury pathways. Am J Kidney Dis 38 2 (2001) 339-348
71. Marengo S.R., Chen D.H., Evan A.P., et al. Continuous infusion of oxalate by minipumps induces calcium oxalate nephrocalcinosis. Urol Res 34 3 (2006) 200-210
72. Marengo S.R., Chen D.H., MacLennan G.T., et al. Minipump induced hyperoxaluria and crystal deposition in rats: a model for calcium oxalate urolithiasis. J Urol 171 3 (2004) 1304-1308
73. Schepers M.S., van Ballegooijen E.S., Bangma C.H., et al. Oxalate is toxic to renal tubular cells only at supraphysiologic concentrations. Kidney Int 68 4 (2005) 1660-1669
74. Holmes R.P., Ambrosius W.T., and Assimos D.G. Dietary oxalate loads and renal oxalate handling. J Urol 174 3 (2005) 943-947 [discussion: 947]
75. Bhandari A., Koul S., Sekhon A., et al. Effects of oxalate on HK-2 cells, a line of proximal tubular epithelial cells from normal human kidney. J Urol 168 1 (2002) 253-259
76. Ebisuno S., Koul H., Menon M., et al. Oxalate transport in a line of porcine renal epithelial cells-LLC-PK1 cells. J Urol 152 1 (1994) 237-242
77. Huang M.Y., Chaturvedi L.S., Koul S., et al. Oxalate stimulates IL-6 production in HK-2 cells, a line of human renal proximal tubular epithelial cells. Kidney Int 68 2 (2005) 497-503
78. Scheid C., Koul H., Hill W.A., et al. Oxalate toxicity in LLC-PK1 cells: role of free radicals. Kidney Int 49 2 (1996) 413-419
79. Khan S.R., Byer K.J., Thamilselvan S., et al. Crystal-cell interaction and apoptosis in oxalate-associated injury of renal epithelial cells. J Am Soc Nephrol 10 Suppl 14 (1999) S457-S463
80. Robertson W.G. Kidney models of calcium oxalate stone formation. Nephron Physiol 98 2 (2004) 21-30
81. Robertson W.G., Peacock M., Marshall R.W., et al. Saturation-inhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract. N Engl J Med 294 5 (1976) 249-252
82. Asplin J.R., Parks J.H., Chen M.S., et al. Reduced crystallization inhibition by urine from men with nephrolithiasis. Kidney Int 56 4 (1999) 1505-1516
83. Hess B. Tamm-Horsfall glycoprotein-inhibitor or promoter of calcium oxalate monohydrate crystallization processes?. Urol Res 20 1 (1992) 83-86
84. Coe F.L., Nakagawa Y., Asplin J., et al. Role of nephrocalcin in inhibition of calcium oxalate crystallization and nephrolithiasis. Miner Electrolyte Metab 20 6 (1994) 378-384
85. Coe F.L., Nakagawa Y., and Parks J.H. Inhibitors within the nephron. Am J Kidney Dis 17 4 (1991) 407-413
86. Kaiser E.T., and Bock S.C. Protein inhibitors of crystal growth. J Urol 141 3 Pt 2 (1989) 750-752
87. Suzuki M., Kobayashi H., Kageyama S., et al. Excretion of bikunin and its fragments in the urine of patients with renal stones. J Urol 166 1 (2001) 268-274
88. Ciftcioglu N., Bjorklund M., Kuorikoski K., et al. Nanobacteria: an infectious cause for kidney stone formation. Kidney Int 56 5 (1999) 1893-1898
89. Kajander E.O., Ciftcioglu N., Miller-Hjelle M.A., et al. Nanobacteria: controversial pathogens in nephrolithiasis and polycystic kidney disease. Curr Opin Nephrol Hypertens 10 3 (2001) 445-452
90. Dorrell S. Nanobacteria linked to kidney disease. Mol Med Today 5 9 (1999) 373
91. Jelic T.M., Malas A.M., Groves S.S., et al. Nanobacteria-caused mitral valve calciphylaxis in a man with diabetic renal failure. South Med J 97 2 (2004) 194-198
92. Wood H.M., and Shoskes D.A. The role of nanobacteria in urologic disease. World J Urol 24 1 (2006) 51-54
93. Piper C., Dreier J., Kleesiek K., et al. Nanobacteria to promote degenerative aortic valve stenosis?. J Heart Valve Dis 15 4 (2006) 499-501
94. Ciftcioglu N., McKay D.S., and Kajander E.O. Association between nanobacteria and periodontal disease. Circulation 108 8 (2003) e58-e59 [author reply: e58-9]
95. Kajander E.O., and Ciftcioglu N. Nanobacteria: an alternative mechanism for pathogenic intra- and extracellular calcification and stone formation. Proc Natl Acad Sci U S A 95 14 (1998) 8274-8279
96. Kajander E.O., Ciftcioglu N., Aho K., et al. Characteristics of nanobacteria and their possible role in stone formation. Urol Res 31 2 (2003) 47-54
97. Vogel G. Bacteria to blame for kidney stones?. Science 281 5374 (1998) 153
98. Shiekh F.A., Khullar M., and Singh S.K. Lithogenesis: induction of renal calcifications by nanobacteria. Urol Res 34 1 (2006) 53-57
99. Goldfarb D.S. Microorganisms and calcium oxalate stone disease. Nephron Physiol 98 2 (2004) 48-54
100. Cisar J.O., Xu D.Q., Thompson J., et al. An alternative interpretation of nanobacteria-induced biomineralization. Proc Natl Acad Sci U S A 97 21 (2000) 11511-11515
101. Chan D, Jarrett T, Kavoussi L, et al. Nanobacteria: role in human renal calculi disease. Paper presented at the17th World Congress on Endourology and SWL, Rhodes, Greece; September 2-5, 1999.
102. Low M, Dallèra SA, Troxel HG, et al. Nanobacteria detection in the serum and urine of urinary stone patients versus normal controls. Paper presented at the 17th World Congress on Endourology and SWL, Rhodes, Greece; September 2-5, 1999.
103. Kramer G., Klingler H.C., and Steiner G.E. Role of bacteria in the development of kidney stones. Curr Opin Urol 10 1 (2000) 35-38
104. Liatsikos E.N., Bernardo N.O., Dinlenc C.Z., et al. Caliceal diverticular calculi: is there a role for metabolic evaluation?. J Urol 164 1 (2000) 18-20
105. Gambaro G., Fabris A., Puliatta D., et al. Lithiasis in cystic kidney disease and malformations of the urinary tract. Urol Res 34 2 (2006) 102-107
106. Raj G.V., Auge B.K., Assimos D., et al. Metabolic abnormalities associated with renal calculi in patients with horseshoe kidneys. J Endourol 18 2 (2004) 157-161
107. Hsu T.H., and Streem S.B. Metabolic abnormalities in patients with caliceal diverticular calculi. J Urol 160 5 (1998) 1640-1642
108. Matin S.F., and Streem S.B. Metabolic risk factors in patients with ureteropelvic junction obstruction and renal calculi. J Urol 163 6 (2000) 1676-1678
109. Matlaga B.R., Miller N.L., Terry C., et al. The pathogenesis of calyceal diverticular calculi. Urol Res 35 1 (2007) 35-40
110. Randall A. Papillary pathology as a precursor of primary renal calculus. J Urol 44 (1940) 580
111. Kuo R.L., Lingeman J.E., Evan A.P., et al. Endoscopic renal papillary biopsies: a tissue retrieval technique for histological studies in patients with nephrolithiasis. J Urol 170 6 Pt 1 (2003) 2186-2189
112. Evan A.P., Coe F.L., Lingeman J.E., et al. Insights on the pathology of kidney stone formation. Urol Res 33 5 (2005) 383-389
113. Coe F.L., Parks J.H., and Asplin J.R. The pathogenesis and treatment of kidney stones. N Engl J Med 327 16 (1992) 1141-1152
114. Kuo R.L., Lingeman J.E., Evan A.P., et al. Urine calcium and volume predict coverage of renal papilla by Randall's plaque. Kidney Int 64 6 (2003) 2150-2154
115. Kim S.C., Coe F.L., Tinmouth W.W., et al. Stone formation is proportional to papillary surface coverage by Randall's plaque. J Urol 173 1 (2005) 117-119 [discussion: 119]
116. Matlaga B.R., Williams Jr. J.C., Kim S.C., et al. Endoscopic evidence of calculus attachment to Randall's plaque. J Urol 175 5 (2006) 1720-1724 [discussion: 1724]
117. Parks J.H., Worcester E.M., Coe F.L., et al. Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. Kidney Int 66 2 (2004) 777-785
118. Mandel N., Mandel I., Fryjoff K., et al. Conversion of calcium oxalate to calcium phosphate with recurrent stone episodes. J Urol 169 6 (2003) 2026-2029
119. Nakagawa Y., Asplin J.R., Goldfarb D.S., et al. Clinical use of cystine supersaturation measurements. J Urol 164 5 (2000) 1481-1485